Rapport Therapeutics (RAPP) Accumulated Depreciation (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Accumulated Depreciation data on file, last reported at $1.9 million in Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 59.5% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 59.5% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 105.39% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $1.9 million, down from $2.0 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for RAPP reached as high as $2.0 million in Q4 2025 and fell as low as $127000.0 in Q4 2023.
• Historically, Accumulated Depreciation has averaged $1.2 million across 4 years, with a median of $1.2 million in 2025.
• Across the five-year window, Accumulated Depreciation surged 659.84% in 2024 and surged 59.5% in 2026, its largest moves.
• Year by year, Accumulated Depreciation stood at $127000.0 in 2023, then jumped by 659.84% to $965000.0 in 2024, then surged by 105.39% to $2.0 million in 2025, then slipped by 2.62% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $1.7 million in Q3 2025.